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Abstract
Glutathione (GSH) represents the major nonprotein thiol in cells and, along-
side with glutathione-dependent enzymes such as glutathione reductase (GR), 
glutathione peroxidase (GPx), and glutathione S-transferase (GST), exerts several 
biological functions including the protection against free radicals and other essen-
tial metabolic reactions within the body. Disturbances in the homeostasis of this 
complex glutathione antioxidant system may damage cells and have been implicated 
with the development and progression of several human diseases. In this context, 
the immune and purinergic systems are also essential, since the dysregulation in 
both systems may also be correlated with numerous diseases. These two networks 
are closely related and control inflammatory responses, especially by the crosstalk 
of signaling molecules, receptors, and enzymes; thus, they can exacerbate or 
slow down the progression of diseases. Based on this background, we aimed to 
provide a general scenario of the purinergic and immune systems and the connec-
tion between both and the modulation of glutathione and glutathione-dependent 
enzyme expression and activity in the context of health and disease.
Keywords: ectonucleotidases, receptors, cytokines, inflammation, reactive species, 
oxidative stress, signaling, activity, metabolism
1. Introduction
Glutathione (GSH) represents the major nonprotein thiol in cells and exerts 
numerous biological functions including the defense against reactive oxygen species 
and reactive nitrogen species (ROS and RNS, respectively). Moreover, GSH partici-
pates in countless cellular and metabolic processes in the body, and, thus, changes 
in its homeostasis can cause irreversible cellular damage and influence the etiology 
and evolution of several human diseases, such as cardiovascular, inflammatory, 
neurodegenerative, and metabolic diseases and cancers, among others [1, 2].
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However, in addition to the direct action of GSH, a second line of defense 
against oxidation is carried out by glutathione-dependent enzymes that counteract 
the negative effects of free radicals. These enzymes are (a) glutathione reductase 
(GR), which regenerates reduced GSH from its oxidized form, glutathione disulfide 
(GSSG); (b) glutathione peroxidase (GPx), which detoxifies the cell from organic 
and inorganic peroxides; and (c) glutathione S-transferase (GST), which catalyzes 
the conjugation of GSH with diverse compounds that are produced in the presence 
of oxidative stress detoxification [3].
Oxidative stress and inflammation are closely linked, and cells elicit antioxidant 
defenses against free radicals, as well as pathogens, and other foreign substances by 
activating immune responses [4]. This results in a sophisticated interaction between 
immune system cells and several molecules released by them to defend the organism 
against microorganisms or damaged cells from injured tissues and maintain tissue 
homeostasis [5]. Nevertheless, when the inflammatory responses are exacerbated 
and the mechanisms of homeostatic control do not work properly, this may trigger 
further tissue damage which is associated with several diseases [6]. Furthermore, 
purinergic signaling, comprised by an intricate network of receptors, enzymes, and 
signaling molecules, has been shown to participate in numerous cellular functions 
in the context of health and disease, especially immunomodulatory functions, since 
the components of the purinergic system are widely expressed in immune cells of 
several tissues [7–9].
In this chapter, we provide a general scenario of the purinergic and immune 
systems and how they interplay by modulating glutathione and glutathione-antioxi-
dant enzymes in the context of health and disease.
2. Purinergic system
The formulation of a purinergic neurotransmission hypothesis was firstly pro-
posed by Geoffrey Burnstock back in 1972 [10]. Burnstock, in his search for answers 
about “what molecule could be the transmitter released during non-cholinergic/
non-adrenergic inhibitory transmission in the gut,” suggested that perhaps adenos-
ine triphosphate (ATP) could fill the criteria based on the following conditions 
needed by a neurotransmitter: (a) the substance must be present within the presyn-
aptic neuron; (b) it must be inactivated by ectoenzymes and/or neuronal uptake; 
(c) it must be released by a Ca2+-dependent mechanism; and (d) specific receptors 
for the substance must be present on the postsynaptic cell [10–12]. Although some 
other researchers had already highlighted the role of purines in blood vessels and 
the heart, and the action of ATP in the autonomic ganglia, the ATP molecule had its 
role as a neurotransmitter discredited in the beginning [11].
Nowadays, however, the existence of a purinergic signaling system is well-
accepted and widely studied because its constituents are found in all tissues of the 
body and associated with immune, nervous, cardiac, hepatic, renal, metabolic, and 
digestive functions, among others. Besides, the purinergic system shows all the cri-
teria needed for ATP to be considered a neurotransmitter. In the following sections, 
the purinergic system components will be discussed in more detail.
2.1 Nucleotides and nucleosides
Nucleotides have three characteristic components: a nitrogenous base (con-
taining nitrogen), a pentose (sugar), and one or more phosphates. The molecule 
without the phosphate group is called nucleoside. Nitrogen bases are derived from 
two related compounds, pyrimidine and purine. The purine bases are adenine 
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(A) and guanine (G), and the pyrimidine bases are cytosine (C), thymine (T), 
and uracil (U). Nucleotides and nucleosides have important roles described in the 
literature such as (a) energy currency in metabolic reactions; (b) chemical bonds 
in cellular responses to hormones and other extracellular stimuli; (c) components 
of an ordered structure of enzymatic cofactors and metabolic intermediates; and 
(d) components in DNA and RNA structures. However, although these are the most 
known properties, purine and pyrimidine nucleotides have other signaling func-
tions described below [13].
The biological properties of pyrimidine and purine nucleotides and nucleosides 
are mainly linked with their binding (or not) to specific receptors. Uridine nucleo-
tide is known by its action in the metabolism of carbohydrates as uridine diphos-
phate (UDP)-glucose and glycogen synthesis. Besides, cUMP is related alongside 
with cCMP as intracellular second messengers. Cytidine is known to form cCMP, 
which has been associated with the control of cell growth and blood cell function; 
however, the intracellular signal transduction pathways are not well-defined [14]. 
Some authors proposed that its mechanism is related to the use of the cGMP signal 
transduction pathway [15]. Furthermore, cytidine (as cytidine triphosphate (CTP)) 
and uridine (which is converted to uridine triphosphate UTP and then to CTP) 
contribute to brain phosphatidylcholine and phosphatidylethanolamine synthesis 
[16]. Thymidine and its associated nucleotides have a role as modulators of active 
anticancer drugs, especially antimetabolites [17].
Guanosine and adenine nucleotides are the most commonly known. For 
example, GTP and cGMP are associated with intracellular signaling in physiological 
events of hormonal regulation; GTP and ATP (as well as CTP) are involved with 
the regulation of allosteric enzymes [18]. It is known that the suppression of GTP 
concentrations could be related to the invasion of melanoma cells and cells from 
other cancer types [19, 20]. Moreover, guanosine nucleotides have a role in immune 
response, cardioprotection, and memory formation, among others [18, 21, 22]. 
Adenine nucleotides, besides being part of the energy metabolism (mainly ATP), 
are also neurotransmitters or signaling molecules that act in the control of cellular 
responses, for example: (a) While ADP stimulates platelet aggregation, adenosine 
(Ado) inhibits this process; (b) While ATP is an excitatory neurotransmitter in the 
central nervous system (CNS), Ado acts in neuroprotection; (c) ATP is a pro-
inflammatory molecule known as a damage-associated molecular pattern (DAMP); 
(d) On the other hand, Ado is an anti-inflammatory molecule. Besides, Ado 
nucleotides are found in all tissues of the body presenting many cellular modulatory 
effects [23–25].
2.2 Purinergic receptors
ATP, ADP, UTP, and UDP bind to P2 receptors, while Ado binds to P1 receptors 
(Figure 1). P2 receptors are subdivided into P2X and P2Y families [26]. P2Y recep-
tors are metabotropic G protein-coupled receptors (GPCRs), and its eight subtypes 
can be divided into two groups, depending on the type of G protein-coupled recep-
tor: P2Y1, P2Y2, P2Y4, and P2Y6 are Gq protein-coupled receptors and activate the 
protein phospholipase Cβ, while P2Y12, P2Y13, and P2Y14 are Gi protein-coupled 
receptors which act by inhibiting adenylate cyclase. P2Y11 is a peculiar receptor 
because it is coupled to Gq and Gs and, thus, causes an increase in the intracellular 
levels of 3′,5′-cyclic adenosine monophosphate (cAMP) and Ca2+ [27, 28].
GPCRs are the largest and most diverse group of membrane receptors. The 
activation of a single G protein can affect the production of second messenger 
molecules such as cyclic AMP, diacylglycerol (DAG), and inositol 1,4,5-trisphos-
phate (IP3). Furthermore, there are mainly three subtypes of G proteins, Gs, Gi, 
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and Gq. The Gs (stimulatory) protein activates adenylate cyclase, which catalyzes 
the formation of cAMP from ATP, being involved in the signaling of many recep-
tors such as glucagon, epinephrine, and calcitonin, among others. The Gq protein is 
involved in the activation of the phospholipase C (PLC) enzyme that participates in 
the formation of second messengers. Once activated, it degrades phosphatidylino-
sitol 4,5-bisphosphate (PIP2) present in the membrane into IP3, and 1,2-DAG. Gp 
protein has important functions in the brain, such as neuronal transmission, 
synaptic plasticity, and neuronal survival. Taking this information into account, 
studies have shown that Gq protein plays an important role in the processes of 
neurodegeneration in Alzheimer’s disease. The Gi (inhibitory) protein inhibits the 
activity of adenylate cyclase enzyme. The Gi isoform, related to the decrease in 
cellular response, is responsible for mediating the inhibitory effects of receptors 
[29, 30]. The biological effects mediated by PY2 purinergic receptors are associated 
with these types of G proteins.
P2X receptors are ionotropic receptors linked to channels in the plasma mem-
brane; they have ATP as an agonist. There are seven different P2X receptor subtypes 
(P2X1–7) that form trimeric receptors [27]. The extracellular domain of these 
receptors contains binding sites for ATP, competitive antagonists, and modulatory 
metal ions. The transmembrane domains form a nonselective cation channel. The 
opening properties of ion channels differ greatly according to the receptor subtype: 
while the homomeric P2X2, P2X4, and P2X7 receptors exhibit slow desensitization, 
the P2X1 and P2X3 receptors exhibit rapid desensitization [31].
P1 receptors, which have Ado as an agonist, are divided into four subtypes, A1, 
A2A, A2B, and A3, and all are G protein-coupled receptors. The A1 receptor medi-
ates signaling responses which may be caused by its coupling to different proteins 
within the Gi/o family. The known pathway of action of this receptor is through 
the inhibition of adenylate cyclase, which causes a decrease in cAMP. Moreover, 
the A1 receptor mechanism of action is through the activation of PLC, which leads 
to an increase in cytosolic calcium. In turn, A2A receptors are Gs protein-coupled 
receptors and activate adenylate cyclase. A2B receptor is coupled to different 
Figure 1. 
Purinergic system components. P1 and P2 receptors, enzymes: ENTPDase, alkaline phosphate, NPP, 
5′-nucleotidase, and adenosine deaminase. Nucleotides and adenosine. Nucleoside transporter (NT) and 
pannexin 1 (channel is an integral component of the P2X/P2Y purinergic signaling). (Authors’ artwork).
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signaling pathways, including guanylate cyclase activation, through PLC-mediated 
Gq coupling, and an increase in Ca2+ concentrations is dependent on IP3. A3 recep-
tors are Gi protein-coupled and also Gq protein-coupled. A2B and A3 receptors 
are known as methylxanthine-insensitive receptors on the contrary of A1 and A2A 
receptors [26, 32, 33].
P1 receptors are widely distributed in metabolically active tissues, such as 
the pancreas, liver, and adipose tissues; they are also present in immune cells, 
indicating an important role in the regulation of immune system responses. The 
A1 receptor is an oxidative stress sensor, and it has shown to have pro- and anti-
inflammatory effects as well as it is associated with the reduction of ischemic events 
[34, 35]. Moreover, A1 receptor activation has been shown during the initial phase 
of leukocyte recruitment, and the A2A receptor is expressed at the resolution phase 
[36]. On the other hand, the activation of the A2A receptor exacerbates neuronal 
damage as well as recruitment and activation of microglia in the CNS [35], although 
some anti-inflammatory effects by its stimulation in immune cells have been 
suggested [37]. A2B receptor has pro- and anti-inflammatory effects. Studies have 
demonstrated that A2B receptors stimulate pro-inflammatory cytokines like IL-4, 
IL-6, IL-8, IL-13, IL-19, and others; it has also been shown to activate human mast 
cells being involved in allergic and inflammatory disorders [33, 34]. A3 receptor is 
widely distributed in the immune tissue, and its functions are related to the release 
of allergic mediators including histamine by mast cells, suggesting a role in inflam-
mation. In the brain, A3 and A1 receptors seem to be associated, as hippocampal A3 
receptors have been shown to desensitize A1 receptors [38]. Moreover, A3 receptors 
were found to act in cardiovascular protection [33].
Both P1 and P2 receptors are located in several tissues, mainly the pancreas, vas-
cular system, CNS, liver, kidney, and immune cells [39–42]. In the CNS, the expres-
sion of these receptors has been shown in many structures and proposed to be 
associated with the development of several pathologies, such as Alzheimer’s disease 
[41, 43]. P2Y receptors, especially, are related to platelet function and thrombus 
promotion [42]. Platelets are known to express P2X1R, P2Y1R, and P2Y12R, where 
ADP signaling predominates through the activation of P2Y1R and P2Y12R, which is 
critical for initiating platelet aggregation [44, 45]. The P2X7 and P2X4 receptors are 
present in the kidney, and their expression can be increased in pathologies involv-
ing inflammatory processes of this tissue [46]. In the liver, the purinergic system 
is involved in the physiological regulation and also plays a role in the pathological 
processes of liver disease. Purinoceptors are also involved in bile secretion and gly-
cogen and lipid metabolism. Moreover, the activation of P2Y1 receptors in human 
and rodent hepatocytes stimulates the glycogen phosphorylase enzyme [40].
It is important to highlight that when high concentrations of ATP bind to the 
P2X7 receptor, it can form pores in the membrane promoting inflammasome 
activation in macrophages and endothelial cells and, subsequently, promoting the 
release of cytokines, such as interleukin-1β (IL-1β), through a caspase-1-dependent 
process [47]. IL-1β is associated with autoinflammatory diseases as well as other 
inflammatory conditions such as hypoxia and hemorrhage. Furthermore, IL-1β 
causes a marked increase in the expansion of naïve and memory CD4+ T cells in 
response to antigens and particularly when used with lipopolysaccharide (LPS) as a 
costimulant [48, 49].
Purinergic receptors, completely unknown 50 years ago, are nowadays widely 
studied as they participate in the modulation of many physiological processes 
and since their up- or downregulation is associated with many diseases. Besides, 
several nucleotides or nucleosides bind to these receptors and trigger their corre-
spondent effects, inhibiting or stimulating downstream pathways. Furthermore, 
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there are also some enzymes whose function is to control the levels of these 
molecules, which will be presented below.
2.3 Ectonucleotidases
The ectonucleotidases are divided mainly into four gene families, which include 
pyrophosphate/phosphodiesterases (ENPPs), alkaline phosphatases, ectonucleoside 
triphosphate diphosphohydrolases (ENTPDases), and 5′-nucleotidases. ENPPs 
act on triphosphate nucleotide (ATP and UTP) hydrolysis into monophosphate 
nucleotides (AMP and UMP) and pyrophosphates. Seven enzymes are found in the 
ENPP family. Two isoforms are capable of hydrolyzing ATP, especially isoforms 
ENPP1 and ENPP3. Moreover, ENPP4 is involved in ADP hydrolysis in platelets, 
and the other isoenzymes hydrolyze phosphodiester bonds into phospholipids. 
Furthermore, ENPP1 is related to bone mineralization and tissue calcification and 
has been described for acting on insulin resistance in diabetic patients [50, 51]. 
NPP2 is expressed mainly in the brain, lung, kidney, endothelial cells, and also 
biological fluids, being associated with intracellular modulation through its binding 
to activated integrins on the target cells [52].
Alkaline phosphatases have a wide substrate specificity for different phos-
phomonoesters and other compounds containing phosphate, including adenine 
nucleotides, inorganic polyphosphates, and pyrophosphates. Three isoenzymes are 
tissue-specific and have 90–98% homology, which are the alkaline phosphatases of 
the intestine, the placenta, and those of germ cells. The last isoenzyme, tissue-non-
specific alkaline phosphatase (TNAP), is approximately 50% identical to the others, 
and it is expressed mainly in the bones, liver, and kidney. TNAP is mostly known for 
its function in bone tissue mineralization [51, 53].
ENTPDases hydrolyze di- and triphosphate nucleotides into mononucleotides 
and inorganic phosphates. For their activity, they require Ca2+ and Mg2+ as cofac-
tors. Eight different genes encode members of the ENTPDase family which differ 
in substrate specificity, cell location, and tissue distribution [53]. Four of them 
(NTPDases 1, 2, 3, and 8) are present on the extracellular surface of the mem-
branes. NTPDases 5 and 6 exhibit cytoplasmic location, while NTPDases 4 and 7 
are entirely located intracellularly, facing the lumen of cytoplasmic organelles [51]. 
Members of the membrane-bound NTPDase family show molecular masses of 
approximately 70–80 kDa, and they are proteins with glycosylated residues. They 
show sequence homology in special regions called “apyrase-conserved regions,” 
which are important for the catalytic activity. These enzymes may exist either in 
monomeric or in oligomeric states constituted by two transmembrane domains 
close to the amino and carboxyterminal groups [51, 54].
Concerning their catalytic activity, different isoenzymes have different sub-
strates affinities. NTPDases 1 and 2 have a preference for hydrolyzing adenine 
nucleotides in the detriment of uracil nucleotides. All membrane-bound NTPDases 
hydrolyze ATP more quickly than ADP. NTPDase 1 is the enzyme that has more 
affinity for ATP; however, it hydrolyzes the ADP product to AMP in the same 
proportion [55]. NTPDase 2 has a great preference for ATP hydrolysis. NTPDases 3 
and 8 hydrolyze ATP and UTP in a similar proportion [56]. Intracellular enzymes 
differ in substrate preference. NTPDases 4, 5, and 6 preferentially hydrolyze NTP 
and NDP, but to a lesser extent ATP and ADP. NTPDases 5 and 6 prefer to hydrolyze 
ATP, but not ADP, while NTPDase 7 preferentially hydrolyzes UTP, CTP, and GTP, 
but has a very low affinity for ATP [53, 57].
The family of NTPDases also differs in their tissue location. NTPDase 1 is mainly 
located in immune cells, for example, lymphocytes, monocytes, and blood vessel 
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endothelial cells, and in the CNS [58–60]. NTPDase 2 is also expressed in blood 
vessels and neuronal progenitor cells [53, 58]. Both NTPDases 1 and 2 are expressed 
in pancreas acinar cells. NTPDase 3 is mainly found in subsets of neurons, epithelial 
cells of the kidney, the upper respiratory system, and the digestive and reproduc-
tive systems [28, 61]. NTPDase 8 has a more restricted expression, being found 
in the liver, kidney, and intestine [62, 63]. Regarding the location of intracellular 
isoenzymes, they have a wider expression, due to their control of nucleotides inside 
the cell [54, 64]. For instance, in the CNS, different isoenzymes are expressed by 
neurons, astrocytes, and microglia [65]. Besides, this variation in isoenzymes may 
change according to distinct brain regions [60].
NTPDases can be coexpressed with another enzyme that continues with the 
nucleotide hydrolysis cascade, such as ecto-5′-nucleotidase (eN—CD73, E.C.3.1.3.5). 
eN is an enzyme anchored to the plasmatic membrane by glycophosphatidyl-
inositol (GPI) with its catalytic site facing the extracellular medium, but it can 
also be found in the soluble form [53]. Mammalian eN consists of two glycoprotein 
subunits linked by non-covalent bonds. Zinc and other divalent metal ions bind to 
the end of the N-terminal domain. This ectoenzyme belongs to a large superfamily 
of metallophosphoesterases that act on different substrates, such as several nucleo-
tides, serine/threonine phosphoproteins, and also sphingomyelins [66, 67].
eN is expressed in many tissues, being more abundant in the colon, kidney, and 
brain and less abundant in the liver, lung, and heart [68]. In the vascular system, eN 
is highly expressed in the endothelia and platelets. However, in immune cells, it is 
only present in some subpopulations of cells [67]. Besides, in the CNS, this enzyme 
can be found in different structures, including the cerebral cortex, hypothalamus, 
cerebellum, hippocampus, and olfactory bulb, among others [60].
Also, eN hydrolyzes ribo- and 5′-monophosphate deoxyribonucleotides to their 
respective nucleosides. Among these nucleotides, the prominent function of eN is 
the hydrolysis of AMP to Ado. According to Dunwiddie and Masino [69], Ado is 
considered a third “purinergic messenger.” This nucleoside regulates many physi-
ological processes, particularly in tissues involved with excitatory stimuli, such as 
the heart and the brain, by reducing their excitatory activity [69]. Ado effects are 
related to fluid transport, induced tolerance to ischemia and reperfusion in the 
cardiovascular system, immunity, and inflammation, among others [53].
Ado levels can be regulated by adenosine deaminase (ADA) enzyme activ-
ity, and in humans, two isoforms are expressed: ADA1 and ADA2. ADA1 is more 
relevant in the purinergic cascade because it catalyzes the irreversible Ado and 
2′-deoxyadenosine deamination into inosine and 2′-deoxy-inosine, respectively. 
ADA1 is widely expressed in the intestine, thymus, spleen, and other lymphoid 
and nonlymphoid tissues; it is also involved in neurotransmission [70]. Moreover, 
liver, monocytes/macrophages, and serum also contain another isoenzyme, ADA2, 
which can be active at sites of inflammation during hypoxia and in areas of tumor 
growth [67]. Studies have shown that the ADA2 structure is precisely designed to 
act in the extracellular environment. ADA2 fits into the new family of adenosine 
deaminase-related growth factors (ADGFs), which play a role in tissue growth. 
Besides, Kaljas et al. [72], when analyzing CD4+ T-cell subsets, showed that ADA2 
particularly binds to regulatory T cells expressing CD39 and lacking the receptor for 
ADA1 [71, 72].
Understanding the regulatory mechanisms of purinergic signaling continues to 
be of great importance to several diseases since the overexpression or suppression 
of nucleotidase activities, receptor expression, and nucleotide/nucleoside levels are 
known to be involved in a variety of pathologies, including cancers and inflamma-
tory, neurodegenerative, and cardiovascular diseases.
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3. Involvement of purinergic signaling in immune responses
Immune responses are the result of a complex interaction between immune cells 
and several soluble factors, aimed to protect the host from the invasion by micro-
organisms or to eliminate apoptotic cells at sites of tissue injury, thus maintaining 
tissue homeostasis [5]. However, an intense inflammatory response, not properly 
balanced by endogenous mechanisms of homeostatic control, can lead to cell and 
tissue damage with the production of free radicals [6]. To avoid excessive oxidative 
stress, cells use different mechanisms to activate the immune system including 
antioxidant defenses and purinergic signaling [4]. It is worth mentioning that, since 
its discovery, purinergic signaling has been shown to mediate a wide range of func-
tions in health and disease, especially immunomodulation and inflammation [9].
Immune cells recognize ATP, released from dying cells and damaged tissues, as 
a danger signal that elicits a variety of inflammatory responses. There is evidence 
that, following tissue injury, purinergic signaling response may be divided into 
three temporal phases [4]. First, an acute phase, when ATP is rapidly released into 
the extracellular space from damaged or stressed cells, accumulates to high levels 
and has chemotactic and excitatory effects on immune cells. Second, there is a 
decrease in the extracellular ratio of ATP/Ado responsible to limit the extent and 
duration of inflammation. Third, there is a chronic phase associated with a low 
extracellular ratio of ATP/Ado to promote tissue remodeling [4]. In the next sec-
tions, the functional role of purines in immune cell responses and the contribution 
of purinergic signaling to the mechanisms of inflammation will be highlighted.
3.1 How does ATP release promote inflammasome activation?
Necrotic and apoptotic cells release ATP, which works as a find-me signal to 
attract macrophages to phagocytose and remove dead or dying cells, a process that 
involves the activation of the NLRP3 inflammasome [73]. The NLRP3 inflamma-
some is a protein complex involved in IL-1β and IL-18 processing that senses a 
variety of signals including infection, tissue damage, and metabolic dysregulation 
[74]. The activation of the NLRP3 inflammasome results in the assembly of scaf-
fold components: the cytoplasmic receptor NLRP3, the adaptor protein ASC, and 
the effector protein caspase-1. This association leads to the activation of caspase-1, 
allowing the processing of pro-IL-1β and pro-IL-18 to their mature and secreted 
forms which are biologically active. IL-1β production is a tightly controlled process 
playing a pivotal role in inflammation and the recruitment of neutrophils [75].
In pathological conditions, high levels of ATP (5 mM) are passively released 
from necrotic cells and act as a pro-inflammatory danger signal, activating the 
NLRP3 inflammasome through binding to the ionotropic P2X7 receptors [76]. 
Thus, the extracellular ATP (eATP) leads to K+ efflux, membrane pore formation, 
and ROS-driven activation [77].
3.2  Purinergic receptors play a crucial role as stimuli for chemotaxis of 
inflammatory cells
Activation of purinergic receptors in immune cells can elicit either positive or 
negative feedback mechanisms and thus can tightly regulate immune responses 
[78]. All P1 and P2 receptor subtypes are expressed by immune cells, in a cell type- 
and differentiation-dependent manner (Table 1).
After an infection, leukocytes are programmed to exit the circulation and move 
toward epicenters of infection/inflammation, guided by chemical gradients of 
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different stimuli. Neutrophils are the most abundant leukocytes in the circulation, 
representing the first line of defense in the innate response. Neutrophils are char-
acterized by a large phenotypic heterogeneity and functional versatility, placing 
these cells as important modulators of inflammatory responses [5]. Under adverse 
conditions, neutrophils release ATP via connexin or pannexin 1 hemichannels, and 
ATP undergoes rapid conversion to Ado via the CD39/CD73 axis expressed on the 
neutrophils surface [79].
Regarding P1 type of receptors, A1 and A3 receptors facilitate neutrophil chemo-
taxis, in part, by upregulating the neutrophil adhesion to tissue injury [80]. In particu-
lar, the stimulation of A1 receptors induces ROS production from activated neutrophils 
favoring bactericidal functions, whereas the activation of A2A receptors down-
regulates ROS generation [81]. Regarding P2 receptors, P2X1 receptors also mediate 
neutrophil chemotaxis negatively regulating systemic neutrophil activation, thereby 
limiting the oxidative response, coagulation, and organ damage [82]. However, P2Y11 
receptors could retain the immune functions of neutrophils and reduce the injurious 
effects of increased neutrophil longevity during inflammation [83].
Phagocytes, such as macrophages, are innate immune cells that play an integral 
role in the defense of the host due to their ability to recognize, engulf, and kill 
pathogens while sending out danger signals via cytokines to recruit and activate 
inflammatory cells [84]. The P2X7 receptor has been suggested to play an important 
role in ATP-induced inflammation because it is mainly expressed on inflammatory 
cells. Furthermore, the role of P2X7 in the protection against neutrophil apoptosis 
has been reported as well as its association with the generation of ROS [85].
Some studies demonstrated the involvement of the P2X7 receptor in several 
responses of macrophages to danger, in particular the proinflammatory response 
mediated by IL-1β secretion, bacterial killing, and the associated macrophage 
death. ATP was shown to promote the maturation and release of IL-1β from mac-
rophages, via P2X7 receptors [84]. Despite the dominant role of P2X7 in macro-
phages, evidence has supported the role of additional receptors. For example, the 
P2Y2 signaling on macrophages contributes to the clearance of apoptotic cells and 
also mediates the potentiation of prostaglandin E2 release involved in the induction 
Purinergic 
receptor
Ligand Immune cell expression Function
A1 Ado Neutrophils and immature DCs Chemotaxis
A2A Ado Most immune cells Anti-inflammatory responses
A2B Ado Macrophages, DCs, 
and mast cells
Promotes IL-6 and VEGF release by 
macrophages and DCs, and drives 
mast cell degranulation
A3 Ado Neutrophils and mast cells Reduces neutrophil chemotaxis and 
stimulates mast cell degranulation
P2X7 ATP CD4+ T cells, CD8+ T cells, Treg 
cells, iNKT cells, macrophages, 
and DCs
Activation of effector T cells, 
Treg cells, iNKT cells, monocytes, 
macrophages, and DCs
P2Y2 ATP/UTP Phagocytes, DCs, monocytes, 
and lymphocytes
Chemotaxis and activation
P2Y6 UDP/UTP Monocytes, macrophages, 
neutrophils, and lymphocytes
Activation
Adapted from Cekic et al. [4].
Table 1. 
Principal purinergic receptors of immune cells: expression and functions.
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of nitric oxide synthase (NOS) [86]. On the other hand, A2B receptor activation by 
Ado was reported to inhibit tumor necrosis factor (TNF)-α expression from macro-
phages, whereas it potentiates NOS and interferon (IFN)-γ expression contributing 
to the inflammatory profile.
Like macrophages, dendritic cells (DCs) are professional antigen-presenting 
cells (APCs), whose main role is to activate adaptive immunity (second defense 
line), thereby maintaining immune homeostasis and tolerance [5]. DCs express 
almost all known P2 receptors; besides, extracellular nucleotides exert multiple 
effects on these cells ranging from chemotaxis to control of cytokine release and 
induction of cell death [87]. Mature DCs mainly express A2A and A2B receptors, 
which have pro-inflammatory effects on these cells [88–90].
Together, macrophages and DCs are APCs responsible for the cell-mediated 
immune response and interaction with T lymphocytes [5]. T cells recognize antigens 
through their T-cell receptors (TCR), located at the immune synapse, and physi-
cally interact with peptides that are presented on major histocompatibility complex 
(MHC) molecules by APCs. This immune interaction causes the activation of T-cell 
receptors on lymphocytes, therefore eliciting T-cell differentiation, cytokine pro-
duction, and cytotoxic activity. Once activated, T cells orchestrate effector immune 
cell function by recruiting macrophages, neutrophils, eosinophils, and basophils to 
sites of infection and inflammation and by increasing the microbicidal activity and 
cytokine and chemokine production of these cells [8].
T cells express many members of the P2X, P2Y, and P1 receptor families, as well 
as the ENTPD1 ectonucleotidase. Purinergic signal amplification in T cells occurs 
mainly through P2X1, P2X4, and P2X7 receptors [8]. A2A receptors are the most 
important receptors in regulating lymphocyte activation, where the overall effect 
is suppressive [91]. A2A receptors inhibit both IL-4 and IFN-γ production by both 
naïve CD4+ T cells and Th1 and Th2 cells.
However, ATP is known to boost the activation of T cells by amplifying the TCR-
induced activation and by increasing IL-2 production by P2X1 and P2X4 receptors 
[92]. Thus, T cells promote strong positive purinergic feedback mechanisms, which 
are further amplified in the confined space of the synaptic cleft. Confinement 
of ATP in the immune synapse results in a powerful autocrine feedback mecha-
nism that facilitates the signal amplification required for antigen recognition 
(Figure 2) [8].
3.3 Role of Ado as a regulator of immune responses
In general, Ado has opposite effects on inflammation compared to ATP, essen-
tially acting as an anti-inflammatory molecule [23]. Ado, for instance, inhibits 
adhesion to endothelial cells, reduces superoxide anion production by neutrophils, 
and lowers the release of pro-inflammatory cytokines (Figure 2) [93]. Besides, 
Ado facilitates the release of IL-10, an anti-inflammatory cytokine, from mono-
cytes [94]. Ado also induces the production of vascular endothelial growth factor 
(VEGF), a potent inducer of angiogenesis and vascular permeability through its 
binding to the A2 receptors [93].
The role of Ado in regulating macrophage activation indicates that this mol-
ecule, by activating A2A, A2B, and A3 receptors, inhibits the production of several 
pro-inflammatory mediators such as TNF-α, IL-6, IL-12, nitric oxide (NO), and 
macrophage inflammatory protein (MIP)-1α by macrophages [95]. In parallel, 
extracellular Ado promotes the release of the anti-inflammatory cytokine IL-10 by 
monocytes and macrophages via A2A and A2B receptors exerting an anti-inflam-
matory effect. Moreover, Ado inhibits Th1 and Th2 differentiation by decreasing 
T-cell proliferation and IL-2 production [93, 95].
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As described above, inflammation appears to be oppositely regulated by extra-
cellular ATP and Ado. At the initiation of inflammation, there are high levels of 
ATP, produced by damaged and stressed cells. High ATP levels promote the rapid 
migration of dendritic cells and macrophages through the activity of pannexin 1 
channels and P1 and P2 receptors that trigger NLRP3 inflammasome activation.
Phagocytes and lymphocytes are recruited by chemoattractants and danger 
signals released from inflamed sites upregulating phagocytosis and other phago-
cyte-killing mechanisms, resulting in the clearance of the dying cells. At the end of 
the inflammatory process, increasing levels of Ado are induced by the breakdown 
of ATP by the ATP-dephosphorylating enzymes and the production of Ado by cells 
at the inflammatory site. This results in increased Ado levels and, consequently, 
inhibits the inflammatory processes.
Therefore, purinergic signaling represents the result of the activity of a com-
plex and heterogeneous “molecular machinery” comprising nucleotide/nucleoside 
molecules, plasma membrane P1 and P2 receptors, and nucleotide-degrading 
enzymes, such as CD39 and CD73, cooperating in the inflammatory microenvi-
ronment and protecting tissues, particularly from immune-mediated excessive 
tissue damage.
4.  The interplay of the purinergic and immune systems in the 
modulation of glutathione antioxidant enzymes
Besides knowing the importance of GPx, GST, and GR in several diseases, stud-
ies have drawn specific attention to the relationship between oxidative stress and 
purinergic signaling. Therefore, the connection between the activity and expres-
sion of glutathione antioxidant enzymes with the purinergic system is highlighted. 
Although many studies showed the relationship between the purinergic system and 
Figure 2. 
Purinergic signaling during inflammation. After cell injury by DAMPs or pathogen-associated molecular 
patterns (PAMPs), apoptotic cells release ATP and other nucleotides by pannexin channels. ATP acts as 
“signal damage” for the recruitment of macrophages and DCs. Extracellular ATP ligates and activates the 
P2 purinergic receptors (P2Rs) and is then degraded by soluble and plasma membrane ectonucleotidases to 
generate ado, which acts at ado receptors (AR). DCs, as antigen-presenting cells, present antigens to the MHC 
of TCR, which promote the release of cytokines such as interleukin-1β (IL-1β), interleukin-10 (IL-10), and 
interferon-gamma (INF-γ), which then recruit neutrophil and T lymphocytes to injured tissues. Ado binds to 
A2 receptors and suppresses inflammation. (Authors’ artwork).
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oxidative stress, they did not directly assess the activity of glutathione-dependent 
enzymes. In this sense, the outcomes in glutathione and purinergic system modula-
tion of some studies addressing different human diseases were summarized in 
Table 2.
One of the studies that addressed the direct relationship between GPx and the 
purinergic system showed that Ado administration upregulated GPx-1 expression 
and activity in endothelial cells [96]. It has been shown that polymorphisms in 
GPx and GST enzyme genes are related to increased risk of developing coronary 
heart disease and stroke and is associated with elevated inflammatory markers and 
increased risk of coronary heart disease in smokers, respectively [97]. Moreover, 
in another study, the administration of an Ado receptor agonist increased GPx and 
GR activities in the heart of rats, and the treatment with an Ado receptor antagonist 
blocked this augmentation, confirming the effect of Ado on glutathione antioxidant 
enzymes [98]. As the generation and release of Ado can increase during acute 
myocardial ischemia, its high concentrations may be sufficient to induce GPx-1 
expression, which results in enhanced cellular tolerance to reactive species (RS) 
and contributes to the cardioprotective role of Ado [96]. In agreement with this, a 
study performed with acute myocardial infarction patients revealed an increase in 
NTPDase activity, with enhanced hydrolysis of adenine nucleotides, which pro-
motes an increased Ado generation [99].
Concerning metabolic diseases, GSH levels in erythrocytes and blood plasma 
were observed to be lower in patients with diabetes or metabolic syndrome (MetS), 
and, consequently, the reduced GSH levels potentiate the effects caused by RS [1]. 
Recent studies have also demonstrated the depletion of the GPx and GST enzymes 
in the liver [100] and heart [101] from rats with MetS. Additionally, Martins et al. 
[102] revealed that subjects with MetS present an increase in NTPDase, 5′-nucleo-
tidase, and NPP activities while decreased ADA activity in platelets. Moreover, an 
increase in ATP and ADP hydrolysis and a decrease in Ado deamination in lympho-
cytes of MetS patients were observed [103]. Further, Madec et al. [104] showed an 
increase in the P2X7 purinergic receptor in human adipocytes, which modulates the 
release of inflammatory cytokines and might contribute to the subclinical inflam-
matory status found and conferring increased cardiovascular risk.
In the same way, Cardoso et al. [105] showed an increase in the nucleotide 
hydrolysis, indicating an augment in NTPDase, 5′-nucleotidase, and ADA activi-
ties in platelets from hypertensive rats, suggesting that hypertension increases Ado 
generation, which acts through A2A receptors. Recently, an increase in NTPDase 
1, NTPDase 3, and CD73 expression and activity in the cortex and in A2A expres-
sion in the hippocampus and cortex in hypertensive rats was also demonstrated 
[106]. Additionally, it has been shown that animals with hypertension induced by 
1,3-dipropyl-8-sulfophenylxanthine (DPSPX), an antagonist of Ado receptors, 
present a redox dysfunction in the initial phase of hypertension, which may be 
explained by the blockade of Ado’s protective effects and increased generation of 
RS. With the interruption of DPSXP administration, Ado seems to be involved in 
the adaptive response to enhance the activity of vascular antioxidant enzymes, such 
as GPx to counteract the increase in RS generation [107].
The purinergic network emerges as a central player in pathophysiological 
conditions particularly linked to immune system regulation including diabetes. 
It has been demonstrated that Ado affects insulin secretion, glucose homeostasis, 
and lipid metabolism through the activation of four Ado receptors [108]. In this 
context, studies demonstrated that activities of enzymes that hydrolyze adenine 
nucleotides and nucleosides were changed in diabetic rats [109, 110]. Moreover, 
the administration of an Ado receptor agonist in diabetic rats caused a decrease 
in the plasma glucose concentration and a decrease in medullary and cortical 
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hydrogen peroxide production, which was associated with a proportional increase 
in GPx activity, illustrating that the activation of Ado receptors may improve 
renal antioxidant capacity and glucose metabolism in diabetic rats. A review 
delineated a central role of purines, their receptors, and enzymes in diabetes by 
demonstrating that the manipulation of the purinergic axis at different levels can 
prevent or exacerbate the development and evolution of both type 1 and type 2 
diabetes [111].
In the same line, a study with obese rats showed a decrease in GPx and GST 
activities, besides a decrease in GSH levels in hepatic and renal tissues. The decrease 
in these enzymatic activities may be due to their rapid consumption and exhaustion 
of stored GSH levels in fighting RS generated during the development of obesity, 
which possibly contributes to the progression of obesity-related problems [112].
Purinergic signaling can be exploited in the development of novel therapeutic 
approaches to treat obesity. Hall et al. [113] showed that ATP could mediate the 
long-term effects of leptin on blood pressure involved in obesity and hypertension, 
and high concentrations have been reported to induce inflammatory responses and 
insulin resistance generation in rat adipocytes [114].
Regarding other metabolic diseases, in a study with an animal model of thyroid 
disorders, GST and GPx activities and GST protein expression in red blood cells of 
hyperthyroid and hypothyroid rats were shown to be increased [115]. On the other 
hand, Baldissarelli et al. [116] demonstrated that the GST activity was decreased in 
patients with post-thyroidectomy hypothyroidism, probably to preserve high levels 
of GSH, which can be used by other reactions in the body, such as the neutralization 
of hydroxyl radicals. Furthermore, the authors also showed an increase in the activ-
ity and expression of NTPDase (CD39) and an increase in 5′-nucleotidase and ADA 
activities, besides a lower concentration of Ado in hypothyroid patients, which was 
positively correlated with RS levels.
The role of GSH in cancer has also been demonstrated since the decrease in the 
activity of antioxidant enzymes, such as GPx, and the increase in the levels of dam-
aged DNA bases due to oxidative damage may lead to the formation of free radicals 
which could induce the appearance of malignant cells [117, 118]. Moreover, Li et al. 
[119] showed that GR inhibition generates oxidative stress and suppresses lung 
metastasis and subcutaneous growth of melanoma in vivo. The tumor microenvi-
ronment is characterized by unusually high concentrations of ATP and Ado. Ado is a 
major determinant of the immunosuppressive tumor milieu. In this sense, preclini-
cal data show that targeting the Ado-generating pathway (CD73) or adenosinergic 
receptors (A2A) relieves immunosuppression and potently inhibits tumor growth 
[120, 121]. In this context, patients with lung cancer showed a decrease in ADA 
activity and an increase in A1 receptor expression in lymphocytes, which may 
contribute to Ado pro-tumor effects by promoting a profile of cytokine levels that 
favors tumor progression [122].
Oxidative stress, which is implicated in the pathophysiology of neurodegenera-
tive diseases, also affects brain astrocytes. P2Y receptors, largely expressed in the 
CNS, are proposed to have a cytoprotective action. In the work of Förster and Reiser 
[123], the potential involvement of P2Y receptors in the antioxidant protection 
against hydrogen peroxide-induced toxicity in rat brain astrocytes was investi-
gated. Cells were incubated with the wide range P2Y receptor agonist adenosine 
5′-(3-thiotriphosphate) (ATPүS) and the particular P2Y1 receptor agonist 2-methyl-
thio-ADP (2MeSADP), and findings showed that levels of GSH were augmented in 
the presence of both agonists. Moreover, the expression of genes involved in GSH 
metabolism also relied on the increase of intracellular Ca2+ mediated by the P2Y 
receptor. Taken together, the authors suggest the participation of P2Y receptors in 
the cytoprotection of astrocytes in the event of oxidative stress.
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In the case of neurodegenerative diseases, studies addressing the relationship 
between glutathione antioxidant enzymes and purinergic signaling have also been 
performed. Recently, the effect of intracerebroventricular injection of streptozotocin 
(ICV-STZ), a model of sporadic dementia of the Alzheimer’s type, and administra-
tion of berberine (BRB) on GSH levels and GST activity was investigated in the 
cerebral cortex and hippocampus of rats [124]. Both, in the cerebral cortex and hip-
pocampus, the STZ-induced Alzheimer’s model significantly decreased GSH levels 
and GST activity; however, treatment with BRB at the doses of 50 and 100 mg/kg was 
able to prevent these alterations induced by STZ in rats. Moreover, BRB at both doses 
also prevented the reduction in NTPDase, 5′-nucleotidase (EC-5′-Nt), and ADA 
activities in synaptosomes of the cerebral cortex and hippocampus. In this sense, the 
authors suggested that BRB could have a neuroprotective activity against oxidative 
stress and purinergic system damage in STZ-induced Alzheimer’s model in rats.
Disease Glutathione 
system
Reference Purinergic system Reference
Acute myocardial 
infarction
↑ GPx in whole 
blood
[125] ↑ NTPDase activity in platelets [99]
↓ GPx in serum [126] ↑ ATP, ADP, and AMP hydrolysis
↑ ADA activity in platelets
[134]
↓ GR in serum [127]
Metabolic 
syndrome (MetS)
↓ GPx and GST 
activities in liver
[100] ↑ NTPDase, 5’-NT, and NPP 
activities in platelets
↓ ADA activity in platelets
[102]
↓ GPx and GST 
activities in the 
heart
↓ GSH levels in the 
heart
[101]
↑ ATP and ADP hydrolysis in 
lymphocytes
↓ ADA activity in lymphocytes
[103]
Diabetes ↓ GPx and GST 
activities in liver
[128] ↑ NTPDase, E-NPP, 5'-NT, and 
ADA activities in platelets
[135]
↓ GST activity in 
liver
[129] ↓ NTPDase activity in the cerebral 
cortex
↓ A1R and ↑A2R in the cerebral 
cortex
[110]
↑ ATP and ADP hydrolysis and 
ADA activity in lymphocytes
↑ NTPDase and ADA activities in 
platelets
↓ ATP and ↑ ADP and AMP 
hydrolysis in serum
[109]
Obesity ↓ GPx and GST 
activities in hepatic 
and renal tissues
↓ GSH levels in 
hepatic and renal 
tissues
[112] ↓ ATP, ADP, and AMP hydrolysis 
in serum
[136]
↑ ADA activity in saliva [137]
Hypo thyroidism ↓ GPx activity in 
serum
↑ T-SH and NPSH 
concentrations in 
platelets
[116] ↑ NTPDase, 5’-NT, and ADA 
activities in platelets
↑ CD39 expression
↓ Ado levels in serum
[116]
↑ T-SH and NPSH 
concentrations in 
serum
[130] ↓ 5’-NT activity in platelets
↑ NPP activity in platelets
↑ AMP and inosine levels in serum
[138]
↑ CD73 in lymphocytes [130]
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5. Conclusions
In summary, purinergic and immune systems, comprised mainly of receptors, 
signaling molecules, and also enzymes, play a key role in many pathologies and 
regulate the functions especially of the immune system. Besides, these two complex 
systems closely interact and may modulate GSH levels as well as the expression and 
activity of glutathione-dependent antioxidant enzymes in both scenarios, health 
and disease. Future studies will possibly provide more details into the mecha-
nisms underlying the regulation of these enzymes and help to expand the current 
knowledge.
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Disease Glutathione 
system
Reference Purinergic system Reference
Hyperthyroidism ↓ GPx activity in 
the hippocampus
[131] ↓ NTPDase and 5’-NT activities 
in platelets
↑ ADA activity in platelets
↑ ATP, ADP, AMP, and inosine 
in serum
↓ Ado levels in serum
[138]
↑ GPx activity in 
the hippocampus
[132]
Hypertension ↑ GPx activity in 
mesenteric arteries
[107] ↑ NTPDase, 5'-NT, and ADA 
activities in platelets
[105]
↓ GST activity in 
the kidney
[133] ↑ NTPDase1, NTPDase3, and 
CD73 expression and activity in 
the cortex
↑ A2A expression in hippocampus 
and cortex
[106]
Alzheimer’s 
disease
↓ GSH and GST 
activity in cortex 
and hippocampus
[124] ↓ NTPDase, 5’-NT, and 
ADA activities in cortex and 
hippocampus
[124]
Table 2. 
Changes in glutathione and purinergic systems during diseases.
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